<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Blood Res</journal-id><journal-id journal-id-type="iso-abbrev">Blood Res</journal-id><journal-id journal-id-type="publisher-id">BR</journal-id><journal-title-group><journal-title>Blood research</journal-title></journal-title-group><issn pub-type="ppub">2287-979X</issn><issn pub-type="epub">2288-0011</issn><publisher><publisher-name>Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23826589</article-id><article-id pub-id-type="pmc">3698405</article-id><article-id pub-id-type="doi">10.5045/br.2013.48.2.154</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Fungemia due to <italic>Trichosporon dermatis</italic> in a patient with refractory Burkitt's leukemia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hashino</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Shojiro</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Morita</surname><given-names>Rena</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kanamori</surname><given-names>Hiroe</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Onozawa</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kawamura</surname><given-names>Takahito</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kahata</surname><given-names>Kaoru</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tokimatsu</surname><given-names>Issei</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sugita</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Akizawa</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Asaka</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Gastroenterology and Hematology, Hokkaido University School of Medicine, Sapporo, Japan.</aff><aff id="A2"><label>2</label>Internal Medicine II, Oita University Faculty of Medicine, Oita, Japan.</aff><aff id="A3"><label>3</label>Department of Microbiology, Meiji Pharmaceutical University, Kiyose, Japan.</aff><aff id="A4"><label>4</label>Department of Clinical Laboratory and Transfusion, Hokkaido University Hospital, Sapporo, Japan.</aff><author-notes><corresp>
Correspondence to: Satoshi Hashino. Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan. <email>shashino@med.hokudai.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2013</year></pub-date><volume>48</volume><issue>2</issue><fpage>154</fpage><lpage>156</lpage><history><date date-type="received"><day>16</day><month>8</month><year>2012</year></date><date date-type="rev-recd"><day>03</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Korean Society of Hematology</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p><bold>TO THE EDITOR:</bold> This is a rare case report of fungemia caused by <italic>Trichosporon dermatis</italic> in a patient with refractory Burkitt's leukemia who was administered prophylactic voriconazole.</p><p><italic>Trichosporon</italic> species may be normal flora in the gastrointestinal tract and transiently colonize the skin and respiratory tracts in humans [<xref ref-type="bibr" rid="B1">1</xref>]. Invasive infection caused by <italic>Trichosporon</italic> has emerged as an opportunistic infection in immunocompromised patients with hematological malignancies, post-SCT malignancies and solid tumors [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. <italic>Trichosporon dermatis</italic> (<italic>T. dermatis</italic>) was recently transferred to <italic>Trichosporon</italic> species from <italic>Cryptococcus humicola</italic> complex [<xref ref-type="bibr" rid="B3">3</xref>]. We report a patient with refractory Burkitt's leukemia whose venous blood culture during the neutropenic period after chemotherapy with administration of prophylactic voriconazole (VRCZ) revealed fungemia caused by <italic>Trichosporon</italic> species. Gene analysis of the stocked sample revealed the detected fungus to be <italic>T. dermatis</italic>. To our knowledge, this case is the first reported case report of fungemia caused by <italic>T. dermatis</italic> during administration of VRCZ.</p><sec><title>CASE</title><p>A 47-year-old female who had suffered from obstructive jaundice and ascites for two months was admitted to our hospital for further examinations. A peripheral blood smear revealed lymphoblastic cells with blue cytoplasm and cytoplasmic vacuoles, and a CT scan showed swelling of multiple lymph nodes in the peritoneal cavity. She was diagnosed as having acute lymphoblastic leukemia of Burkitt's type confirmed by karyotype analysis of a bone marrow aspiration sample showing 47, XX, <italic>t</italic>(8;14)(q24;q32), +mar in 9 out of 20 cells and FISH analysis of bone marrow showing IgH/c-MYC fusion signals. Combination chemotherapy with rituximab+hyper CVAD followed by high-dose methotrexate/cytosine arabinoside was started using a central venous catheter (CVC), but she could not obtain complete remission (CR) because of early regrowth of lymphoblasts in bone marrow after the induction chemotherapy (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Thereafter, salvage chemotherapy with rituximab+IVAC and rituximab+ CODOX-M was started, but she could not obtain CR because of central nervous system involvement of leukemic cells. Fluconazole (FLCZ) at 200 mg/day had been administered as a prophylactic anti-fungal drug since the start of initial chemotherapy. Three months after the start of chemotherapy, serum &#x003b2;D-gulucan became positive, and the anti-fungal drug was therefore changed from FLCZ to VRCZ because of covering aspergillosis even without characteristic features of aspegillosis shown by a CT scan of the chest and sinus. After that, galactomannan and &#x003b2;D-gulucan remained negative, but she was administered prophylactic VRCZ at 300 mg BID because of transient increase of galactomannan and continuous myelosuppression after repeated chemotherapy (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Nine months after the diagnosis, she suffered from high fever in a severe neutropenic period (white blood cell count of 0.1-0.6&#x000d7;10<sup>6</sup>/L) after salvage chemotherapy. Venous blood culture taken through the CVC showed <italic>Corynebacterium</italic> species and <italic>Trichosporon mucoides</italic> (<italic>T. mucoides</italic>) by a conventional morphological identification method. At that time, both <italic>Cryptococcus</italic> antigen and &#x003b2;D-gulucan were negative and culture of the removed CVC was also negative. Although the optimal therapy for invasive trichosporonosis is still not known and the identified <italic>Trichosporon</italic> was susceptible to VRCZ <italic>in vitro</italic> (MIC was 0.060 &#x000b5;g/mL), clinical anti-fungal effect of the drug was not sufficient. Therefore, VRCZ was switched to L-amphotericin B (L-AMB). Thereafter, <italic>Trichosporon</italic> species was not identified by repeated venous blood samplings. She died of refractory leukemia 2 weeks after the diagnosis of fungemia by <italic>Trichosporon</italic>. The stocked isolate was genetically analyzed later and identified as belonging to <italic>T. dermatis</italic> by DNA sequencing of the intergenic spacer 1 region [<xref ref-type="bibr" rid="B4">4</xref>].</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Several species of <italic>Trichosporon</italic> have been reported to cause opportunistic fungemia [<xref ref-type="bibr" rid="B5">5</xref>]. <italic>T. dermatis</italic> was newly detected from an infected human skin lesion and was also recognized as a cause of summer-type hypersensitivity pneumonitis (SHP) [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B6">6</xref>]. <italic>T. dermatis</italic> is closely related to <italic>T. mucoides</italic> morphologically and biochemically and is easily misdiagnosed as <italic>T. mucoides</italic> [<xref ref-type="bibr" rid="B7">7</xref>]. Therefore, previous reports concerning trichosporonemia should be reevaluated. Although it had been unknown whether this species was pathogenic to humans, fungemia caused by <italic>T. dermatis</italic> has been reported since 2006 [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>]. Retrospective gene analysis of 22 <italic>Trichosporon</italic> sp. blood stream isolates sequentially obtained from different patients in Brazil showed only one case of <italic>T. dermatis</italic> [<xref ref-type="bibr" rid="B9">9</xref>]. Similarly, Ruan et al. reported that no <italic>T. dermatis</italic> infection was identified from 14 patients with fungemia [<xref ref-type="bibr" rid="B1">1</xref>]. Although Rodriguez-Tudela et al. documented eight cases of <italic>T. dermatis</italic> causing infections, only one case showed bloodstream infection [<xref ref-type="bibr" rid="B10">10</xref>]. Therefore, fungemia caused by <italic>T. dermatis</italic> is very rare. Although Fekkar et al. reported that <italic>T. dermatis</italic> antigens were cross-reactive with both <italic>Aspergillus</italic> galactomannan and <italic>Cryptococcus</italic> capsular antigen, serum of our patient did not show cross-reactivity [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Fungemia caused by <italic>T. dermatis</italic> in our patient occurred during administration of prophylactic VRCZ and levofloxacin at standard doses. Although amphotericin B and echinocandins were not active against <italic>Trichosporon</italic> isolates <italic>in vitro</italic>, azoles, especially VRCZ, have been reported to show good potency [<xref ref-type="bibr" rid="B1">1</xref>]. <italic>In vitro</italic> susceptibility testing of <italic>T. dermatis</italic> to antifungal agents has been reported to be similar to that of other pathogenic <italic>Trichosporon</italic> species [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B9">9</xref>], and it was in fact also susceptible to VRCZ <italic>in vitro</italic> in this case. Profound immunosuppression after repeated chemotherapy, severe neutropenia and oral administration might be the main reasons for the ineffectiveness of VRCZ at a standard dose. Monitoring plasma VRCZ levels might be necessary to avoid subtherapeutic levels [<xref ref-type="bibr" rid="B11">11</xref>]. Risk factors for invasive trichosporonosis are prior antibiotic therapy, use of a central catheter, malignancy, prior chemotherapy and neutropenia, all of which were present in our patient and all of which are also risk factors for candidemia [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. Since fungemia by <italic>T. dermatis</italic> was resolved after removing the central venous catheter in this patient, the influence of central venous catheter might be a major reason of fungemia. Although the clinical effect of L-AMB in our patient was not clear because of early death after the switch of agents, <italic>Trichosporon</italic> species was no longer identified by repeated venous blood samplings. Careful attention should be paid to breakthrough fungal infection in patients with severe innmunosupression and neutropenia even if they are administered wide-spectrum anti-fungal drugs.</p><p>In conclusion, this is the first report of <italic>T. dermatis</italic> infection during administration of VRCZ. Careful attention should be paid to invasive fungal infection in patients with immunosuppression even with administration of prophylactic anti-fungal drugs because of the high mortality rate of invasive trichosporonosis, especially in patients with malignancies [<xref ref-type="bibr" rid="B1">1</xref>]. Molecular techniques are necessary for accurate and definitive diagnosis of trichosporonosis.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>No potential conflicts of interest relevant to this article were reported.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>SY</given-names></name><name><surname>Chien</surname><given-names>JY</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name></person-group><article-title>Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><fpage>e11</fpage><lpage>e17</lpage><pub-id pub-id-type="pmid">19489711</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girmenia</surname><given-names>C</given-names></name><name><surname>Pagano</surname><given-names>L</given-names></name><name><surname>Martino</surname><given-names>B</given-names></name><etal/></person-group><article-title>Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature</article-title><source>J Clin Microbiol</source><year>2005</year><volume>43</volume><fpage>1818</fpage><lpage>1828</lpage><pub-id pub-id-type="pmid">15815003</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>T</given-names></name><name><surname>Takashima</surname><given-names>M</given-names></name><name><surname>Nakase</surname><given-names>T</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>R</given-names></name><name><surname>Shinoda</surname><given-names>T</given-names></name></person-group><article-title>Two new yeasts, Trichosporon debeurmannianum sp. nov. and Trichosporon dermatis sp. nov., transferred from the Cryptococcus humicola complex</article-title><source>Int J Syst Evol Microbiol</source><year>2001</year><volume>51</volume><fpage>1221</fpage><lpage>1228</lpage><pub-id pub-id-type="pmid">11411691</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>R</given-names></name><name><surname>Matsushima</surname><given-names>T</given-names></name><name><surname>Shinoda</surname><given-names>T</given-names></name></person-group><article-title>Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species</article-title><source>J Clin Microbiol</source><year>2002</year><volume>40</volume><fpage>1826</fpage><lpage>1830</lpage><pub-id pub-id-type="pmid">11980969</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Al-Mahmeed</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>ZU</given-names></name></person-group><article-title>Characterization of Trichosporon species isolated from clinical specimens in Kuwait</article-title><source>J Med Microbiol</source><year>2005</year><volume>54</volume><fpage>639</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">15947428</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>R</given-names></name><name><surname>Nishikawa</surname><given-names>A</given-names></name></person-group><article-title>Analysis of Trichosporon isolates obtained from the houses of patients with summer-type hypersensitivity pneumonitis</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>5467</fpage><lpage>5471</lpage><pub-id pub-id-type="pmid">15583267</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname><given-names>SR</given-names></name><name><surname>Reveles</surname><given-names>XT</given-names></name><name><surname>Hamlington</surname><given-names>JD</given-names></name><name><surname>Sadkowski</surname><given-names>LC</given-names></name><name><surname>Johnson-Pais</surname><given-names>TL</given-names></name><name><surname>Jorgensen</surname><given-names>JH</given-names></name></person-group><article-title>Use of DNA sequencing analysis to confirm fungemia due to Trichosporon dermatis in a pediatric patient</article-title><source>J Clin Microbiol</source><year>2006</year><volume>44</volume><fpage>1175</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">16517924</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekkar</surname><given-names>A</given-names></name><name><surname>Brun</surname><given-names>S</given-names></name><name><surname>D'Ussel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum cross-reactivity with Aspergillus galactomannan and cryptococcal antigen during fatal disseminated Trichosporon dermatis infection</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><fpage>1457</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">19824853</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chagas-Neto</surname><given-names>TC</given-names></name><name><surname>Chaves</surname><given-names>GM</given-names></name><name><surname>Melo</surname><given-names>AS</given-names></name><name><surname>Colombo</surname><given-names>AL</given-names></name></person-group><article-title>Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing</article-title><source>J Clin Microbiol</source><year>2009</year><volume>47</volume><fpage>1074</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">19225102</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Tudela</surname><given-names>JL</given-names></name><name><surname>Diaz-Guerra</surname><given-names>TM</given-names></name><name><surname>Mellado</surname><given-names>E</given-names></name><etal/></person-group><article-title>Susceptibility patterns and molecular identification of Trichosporon species</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>4026</fpage><lpage>4034</lpage><pub-id pub-id-type="pmid">16189076</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trifilio</surname><given-names>S</given-names></name><name><surname>Pennick</surname><given-names>G</given-names></name><name><surname>Pi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>1532</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">17351937</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez</surname><given-names>JA</given-names></name></person-group><article-title>Trichosporon infection</article-title><source>Curr Fungal Infect Rep</source><year>2010</year><volume>4</volume><fpage>52</fpage><lpage>58</lpage></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Time course for a patient with refractory Burkitt's leukemia who suffered from fungemia due to <italic>Trichosporon dermatis</italic> after chemotherapy. Abbreviations: R-hyper CVAD, rituximab+cyclophosphamide hydrate+vincristine sulfate+doxorubicin hydrochloride+dexamethasone; MTX, methotrexate; R-IVAC, rituximab+ifosfamide+etoposide+cytarabine; R-CODOX-M, rituximab+cyclophosphamide hydrate+vincristine sulfate+doxorubicin hydrochloride+methotrexate; PBSCC, peripheral blood stem cell collection; R-ASHAP, rituximab+doxorubicin hydrochloride+methylprednisolone+cytarabine+cisplatin; MEAM, ranimustine+etoposide+cytarabine+melphalan; FLCZ, fluconazole; VRCZ, voriconazole; ITCZ, itraconazole; L-AMB, liposomal amphotericin B; CVC, central venous catheter.</p></caption><graphic xlink:href="br-48-154-g001"/></fig></floats-group></article>